Precision BioSciencesDTIL
NASDAQBiotech
No cached AI snapshot yet for DTIL.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
68 employees25.80M shares outstandinglisted 2019-03-28
Next earnings ~May 5, 2026
About Precision BioSciences
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Latest News
Showing market-wide stock news
What history says about longer-term bond yields after the first Fed hike
Global Market: European shares recover as oil rally pauses ahead of Fed decision
How The Fed Has Been Quietly Tightening Ahead Of The Expected Rate Hike
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Related Stocksin Biotech
Ready to see the live AI view on DTIL?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing DTIL side-by-side with live signals.